Ambica International Corporation Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: Ambica International Corporation Pharmaceutical Import Records from India — 9 Products, $5.6M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ambica International Corporation — Pharmaceutical Importer Profile (2026) | 9 Products, $5.6M Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Ambica International Corporation?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Xl Laboratories Private Limited	$5.6M	441	14.3%
Unicure Remedies Private Limited	$4.8M	305	12.4%
Unosource Pharma Limited	$3.5M	234	9.1%
Reliance Life Sciences Private Limited	$3.2M	82	8.1%
Rainbow Life Sciences Private Limited	$2.8M	318	7.2%
Brawn Laboratories Limited	$2.5M	179	6.4%
Cooper Pharma Limited	$2.0M	186	5.2%
Wockhardt Limited	$1.6M	64	4.2%
Agio Pharmaceuticals Limited	$1.6M	155	4.1%
Cadila Pharmaceuticals Limited	$1.6M	113	4.0%
Medley Pharmaceuticals Limited	$1.1M	98	2.7%
Giyaan Pharma Private Limited	$983.1K	67	2.5%
Nabros Pharma Private Limited	$897.7K	52	2.3%
Getwell Pharmaceuticals	$837.3K	103	2.1%
J B Chemicals And Pharmaceuticals Limited	$538.3K	40	1.4%
Mediwin Pharmaceuticals	$493.7K	45	1.3%
Zeiss Pharmaceuticals Private Limited	$475.1K	28	1.2%
Maneesh Pharmaceuticals Limited	$462.4K	21	1.2%
Getwell Pharma India Private Limited	$405.8K	38	1.0%
Unique Biotech Limited	$362.7K	23	0.9%
Westcoast Pharmaceutical Works Limited	$323.6K	22	0.8%
Synmedic Laboratories	$320.1K	53	0.8%
Theon Pharmaceuticals Limited	$283.9K	17	0.7%
Innova Captab Limited	$283.3K	20	0.7%
Virchow Healthcare Private Limited	$236.0K	11	0.6%
Neomi Pharmaceuticals Private Limited	$231.7K	13	0.6%
Sydler Remedies Private Limited	$189.3K	18	0.5%
Lyka Labs Limited	$175.5K	10	0.4%
J B Chemicals Pharmaceuticals Limited	$160.7K	11	0.4%
Admac Lifesciences	$154.0K	12	0.4%

Ambica International Corporation sources from 49 verified Indian suppliers across 2,041 distinct formulations. The supply base is diversified across 49 suppliers, reducing single-source dependency risk.

What Formulations Does Ambica International Corporation Import?

Formulation	Value	Ships
Potassium citrate extended release	$399.6K	26
Immunorel 100ML (brp-052) immunoglobulinnormal, human 5% (50MG/ML) solution fori.v. infusion 100ML vial {human	$300.0K	6
Potassium citrate extended relase	$235.4K	5
Immunorel 100 ML immunoglobulin normal	$200.0K	6
Pharmaceuticals drugs and medicines-	$188.3K	14
Trimetazidine hcl 35 MG modified	$174.3K	6
Omeprazole delayed release capsules 40MG	$161.1K

What Products Does Ambica International Corporation Import?

Top Products by Import Value

1Immunoglobulin$2.5M 2Pioglitazone$601.5K 3Natural$600.0K 4Colchicine$480.7K 5Folic$398.4K 6Glimepiride$337.5K

Import Portfolio — Top 9 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Immunoglobulin	Other	$2.5M	49	1.4%	2
2	Pioglitazone	Diabetes & Endocrine	$601.5K	59	1.6%

Key Metrics

Total Import Value$5.6M

Products9

Shipments300

Categories7

CountryPhilippines

#1 Rankings0

Indian Suppliers49

Formulations2,041

Top Categories

Other44.1%

Diabetes & Endocrine16.9%

Last updated: March 28, 2026

Ambica International Corporation — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Ambica International Corporation is a leading pharmaceutical company based in Parañaque City, Metro Manila, Philippines. Established in 2003, the company specializes in the importation, distribution, marketing, and sale of a diverse range of medical products, including branded generics, patented drugs, and nutraceuticals. With a robust portfolio covering at least 26 therapeutic segments, Ambica caters to a wide spectrum of healthcare needs, ensuring optimal efficacy and safety.

The company's mission is to provide high-quality healthcare products and services that are accessible and affordable to everyone, advocating for the health and well-being of the communities it serves. Ambica's strategies are anchored in four core values: Accessibility, Availability, Affordability, and Advocacy. These principles guide their operations, aiming to eliminate barriers to healthcare, ensure a robust supply chain, bridge economic divides, and promote health literacy and public health initiatives.

2Distribution Network

Ambica International Corporation operates a comprehensive distribution network across the Philippines, ensuring that its products are readily available in leading drug stores and hospitals nationwide. The company's headquarters are located at No. 9 Amsterdam Extension, Merville Park Subdivision, Parañaque City, Metro Manila. Additionally, Ambica maintains a branch office at 3270-A Armstrong Ave, Merville Access Road, Pasay City, Philippines.

Supplier Relationship Intelligence — Ambica International Corporation

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Ambica International Corporation's sourcing strategy exhibits a high degree of concentration, with the top five products accounting for 81.6% of the total import value. This concentration indicates a strategic focus on specific high-demand products, potentially allowing for better negotiation terms and streamlined supply chain management. However, such dependency on a limited product range could pose risks if market dynamics shift or if there are disruptions in the supply of these key products.

The company's reliance on a diverse set of suppliers, with 49 unique Indian suppliers, suggests a strategic approach to mitigate risks associated with single-source dependency. This diversified supplier base enhances the stability and resilience of Ambica's supply chain, reducing the impact of potential disruptions from any single supplier.

2Supply Chain Resilience

Ambica International Corporation's supply chain resilience is bolstered by its diversified supplier base, encompassing 49 unique Indian suppliers. This diversity mitigates risks associated with single-source dependency, ensuring a more stable and adaptable supply chain. The company's focus on importing finished pharmaceutical formulations, rather than raw APIs or bulk drugs, indicates a strategic choice to streamline operations and maintain product quality.

While specific details about backup suppliers and shipping route exposures are not publicly disclosed, Ambica's extensive network of suppliers and its commitment to regulatory compliance suggest a proactive approach to maintaining supply chain integrity. The company's partnerships with world-renowned manufacturers with state-of-the-art facilities approved by highly regulated drug authorities, such as the USFDA, UKMHRA, TGA, EUGMP, and PICs member authorities, further enhance the resilience and reliability of its supply chain.

3Strategic Implications

Ambica International Corporation's sourcing pattern, characterized by a high concentration on specific products and a diversified supplier base, positions the company to leverage economies of scale and negotiate favorable terms with suppliers. This strategy enhances its competitive position in the Philippine pharmaceutical market by ensuring a steady supply of high-demand products.

For Indian exporters, the opportunity lies in aligning their product offerings with Ambica's focus areas, particularly in the therapeutic categories where Ambica has a significant presence. By ensuring compliance with the regulatory standards of both India and the Philippines, and by offering products that meet the quality expectations of Ambica, Indian exporters can establish mutually beneficial partnerships.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

In the Philippines, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation, distribution, and marketing of pharmaceutical products. The FDA's responsibilities include product registration, licensing of establishments, post-market surveillance, and enforcement against unregistered health products. Key legislation governing pharmaceutical imports includes the Food, Drug, and Cosmetic Act (Republic Act No. 3720) and the FDA Act of 2009 (Republic Act No. 9711).

The marketing authorization pathway for Indian generics involves obtaining a Certificate of Product Registration (CPR) from the Philippine FDA. This process requires compliance with the FDA's standards, including submission of necessary documentation, quality control test results, and adherence to Good Manufacturing Practice (GMP) guidelines. Additionally, the FDA has implemented measures to simplify the export process for pharmaceutical products, enhancing the efficiency of product registration and distribution. (pna.gov.ph)

2Import Licensing & GMP

Import licensing requirements in the Philippines mandate that pharmaceutical importers, such as Ambica International Corporation, obtain a License to Operate (LTO) from the FDA. This license authorizes the company to import, export, and wholesale pharmaceutical products. Ambica holds an active LTO, indicating its compliance with the FDA's regulatory standards. (verification.fda.gov.ph)

The recognition of Good Manufacturing Practice (GMP) certificates is crucial for ensuring product quality and safety. The Philippine FDA recognizes GMP certifications from reputable authorities, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Manufacturers supplying Ambica's imported products are expected to adhere to these recognized GMP standards to meet the regulatory requirements of the Philippines.

3Quality & Labeling

Pharmaceutical products imported into the Philippines must undergo batch testing to ensure compliance with quality standards. Stability requirements are enforced to guarantee that products maintain their efficacy and safety throughout their shelf life. Labeling language requirements stipulate that product labels be in English and Filipino, providing clear and accurate information to consumers. Serialization mandates are implemented to enhance traceability and prevent counterfeit products from entering the market.

4Recent Regulatory Changes

Between 2024 and 2026, the Philippine FDA has implemented measures to simplify the export process for pharmaceutical products. Administrative Order No. 2024-0012, titled "Prescribing the Rules and Regulations on the Registration of Pharmaceutical Products and Active Pharmaceutical Ingredients Intended Solely for Export," was issued to enhance the efficiency of product registration and distribution. These changes aim to strengthen the health sector and expedite the distribution of medicines to the public. (pna.gov.ph)

TransData Nexus Research · Philippines regulatory databasesMar 2026

Ambica International Corporation — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Ambica International Corporation's product category focus is strategically aligned with the therapeutic areas of high demand in the Philippine market. The company's top five imported products—Immunoglobulin, Pioglitazone, Natural, Colchicine, and Folic—reflect a targeted approach to address prevalent health conditions. The significant import value of Immunoglobulin, for instance, indicates a strategic emphasis on critical care and immunology, catering to the substantial demand for such treatments.

The market demand driving these imports is influenced by factors such as the prevalence of specific diseases, the availability of effective treatments, and the economic accessibility of these medications. Ambica's focus on these therapeutic areas demonstrates a keen understanding of the healthcare needs of the Filipino population and a commitment to providing essential medications that improve health outcomes.

2Sourcing Profile

Ambica International Corporation's sourcing strategy is centered on importing finished pharmaceutical formulations from India, rather than raw Active Pharmaceutical Ingredients (APIs) or bulk drugs. This approach allows the company to streamline operations, ensure consistent product quality, and meet the regulatory requirements of both India and the Philippines. India's robust pharmaceutical manufacturing sector, with its adherence to recognized GMP standards, aligns well with Ambica's sourcing needs.

The company's diversified supplier base, comprising 49 unique Indian suppliers, indicates a strategic effort to mitigate risks associated with single-source dependency. This diversification enhances the stability and resilience of Ambica's supply chain, ensuring a steady and reliable supply of pharmaceutical products to meet market demands.

3Market Positioning

Based on its product mix, Ambica International Corporation serves a broad segment of the Philippine pharmaceutical market, including retail pharmacies,

TransData Nexus Research · DGFT trade data analysisMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Ambica International Corporation identified across shipments using consignee name normalization.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Ambica International Corporation's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 300 individual customs records matching Ambica International Corporation.
5.Supplier Verification: Ambica International Corporation sources from 49 verified Indian suppliers across 2,041 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

9 Products Tracked

7 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Ambica International Corporation

Ambica International Corporation — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Ambica International Corporation?

What Formulations Does Ambica International Corporation Import?

What Products Does Ambica International Corporation Import?

Top Products by Import Value

Import Portfolio — Top 9 by Import Value

Key Metrics

Top Categories

Ambica International Corporation — Corporate Profile & Information

1Company Overview

2Distribution Network

Ambica International Corporation Therapeutic Categories — 7 Specializations

Indian Suppliers

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — Ambica International Corporation

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into Philippines — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

Ambica International Corporation — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Frequently Asked Questions — Ambica International Corporation

What products does Ambica International Corporation import from India?

Who supplies pharmaceuticals to Ambica International Corporation from India?

What is Ambica International Corporation's total pharmaceutical import value?

What therapeutic categories does Ambica International Corporation focus on?

Get Full Ambica International Corporation Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology